HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a $15 price target.
August 15, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Lisata Therapeutics and maintained a $15 price target, which could positively impact the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and a maintained price target of $15 by HC Wainwright & Co. indicates their continued confidence in Lisata Therapeutics, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100